NicErase-SL lobeline sulfate sublingual tablet data

DYGN (Cambridge, Mass.) announced that preliminary, pilot Phase III results show efficacy, including some statistically significant outcomes, with twice the quit rates in those treated for six weeks, compared to placebo.

The trial of the under-the-tongue tablet was conducted in 180 people. No further details on the data were made available. ...